Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Futura Medical ( (GB:FUM) ).
Futura Medical reported its financial results for the first half of 2025, revealing challenges in market uptake for its flagship product, Eroxon, which has been launched in 25 countries. The company experienced a significant drop in revenue to £1.0m, primarily due to slower than expected sales, resulting in a loss after tax of £6.59m. The company is undergoing a strategic review to address these issues, exploring cost-cutting measures and potential partnerships to extend its cash runway. Despite current setbacks, Futura remains optimistic about the potential of its products, including Eroxon Intense and WSD4000, and continues to pursue regulatory approvals and market expansion.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare group specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their core strength lies in research, development, and commercialization of topically delivered gel formulations, with key products including Eroxon, Eroxon Intense, and WSD4000. Eroxon is a topical gel treatment for erectile dysfunction, while WSD4000 targets symptoms of impaired sexual response and function in women.
Average Trading Volume: 1,194,034
Technical Sentiment Signal: Sell
Current Market Cap: £10.01M
See more data about FUM stock on TipRanks’ Stock Analysis page.